WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1891-01-01

Employees: 10K

Market Cap: -

Website: http://www.medschool.wustl.edu

Clinical Trials

Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors

Phase 1

Withdrawn

Conditions: Pediatric Brain Tumor

Interventions: Biological: Personalized peptide vaccine
Drug: Poly ICLC
Procedure: Peripheral blood draw

First Posted Date: 2017-03-03

Last Posted Date: 2021-05-25

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT03068832

Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: CIML NK Cell Infusion
Procedure: CD3+ T Cell Product Infusion

First Posted Date: 2017-03-03

Last Posted Date: 2024-10-01

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 110

Registration Number: NCT03068819

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia

Phase 2

Terminated

Conditions: Acute Myeloid Leukemia, Relapsed, Adult
Acute Myeloid Leukemia

Interventions: Drug: Decitabine
Procedure: Bone marrow biopsy/aspirate
Procedure: Peripheral blood draw
Procedure: Skin biopsy
Procedure: Buccal swab

First Posted Date: 2017-02-24

Last Posted Date: 2022-06-02

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 17

Registration Number: NCT03063203

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Cochlear Implantation in Adults With Asymmetric Hearing Loss Clinical Trial

Not Applicable

Completed

Conditions: Hearing Loss

Interventions: Device: Cochlear implant

First Posted Date: 2017-02-14

Last Posted Date: 2022-01-12

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 40

Registration Number: NCT03052920

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States
🇺🇸
House Clinic, Los Angeles, California, United States
🇺🇸
Saint Luke's Midwest Ear Institute, Kansas City, Missouri, United States

and more 1 locations

Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma in Relapse

Interventions: Drug: Elotuzumab
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2017-01-24

Last Posted Date: 2024-12-18

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 25

Registration Number: NCT03030261

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Colorado Blood Cancer Institute (Sarah Cannon), Denver, Colorado, United States
🇨🇦
University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Outcomes Study in Patients Receiving Aspirin With Mechanical Compression Devices Versus Aspirin Alone Following Knee and Hip Arthroplasty

Phase 4

Withdrawn

Conditions: PE - Pulmonary Thromboembolism
DVT - Deep Vein Thrombosis

Interventions: Drug: Aspirin
Device: (Post- discharge) Mechanical Compression Device

First Posted Date: 2017-01-23

Last Posted Date: 2017-05-12

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT03027167

Alirocumab and Reverse Cholesterol Transport

Phase 1

Completed

Conditions: Atherosclerosis
Coronary Heart Disease

Interventions: Drug: Alirocumab
Drug: Placebos

First Posted Date: 2017-01-09

Last Posted Date: 2018-11-07

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 28

Registration Number: NCT03014830

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

Phase 2

Completed

Conditions: Cancer of Breast
Breast Carcinoma
Breast Cancer
Malignant Tumor of Breast

Interventions: Drug: Palbociclib
Drug: Letrozole
Drug: Fulvestrant
Procedure: Optional research biopsy
Drug: Goserelin
Procedure: Research blood draw
Procedure: Circulating tumor cell blood draw
Procedure: Tumor biopsy (optional)

First Posted Date: 2017-01-02

Last Posted Date: 2024-03-20

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 55

Registration Number: NCT03007979

Locations: 🇺🇸
University of Nebraska, Lincoln, Nebraska, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia

Phase 1

Withdrawn

Conditions: Healthy Participants
Cervical Cancer
Bladder Cancer
Pelvic Neoplasms
Soft-tissue Sarcoma
Rectal Cancer

Interventions: Device: Magnetic Resonance-guided High-Intensity Focused Ultrasound

First Posted Date: 2017-01-02

Last Posted Date: 2017-10-06

Lead Sponsor: Washington University School of Medicine

Registration Number: NCT03007771

Improving Follow-Up for Discharged Emergency Care Patients

Not Applicable

Completed

Conditions: General Medicine
Mobile Health
Emergency Medicine

Interventions: Device: Epharmix/CareSignal eHealth

First Posted Date: 2016-12-23

Last Posted Date: 2020-11-24

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 327

Registration Number: NCT03002311

Locations: 🇺🇸
Barnes Jewish Hospital, Saint Louis, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy